Patient advocacy communities such as Johnson & Johnson’s IBD Social Circle can quell the feelings of loneliness and isolation common in those with IBD, the company explains in a new report.

At the American College of Allergy, Asthma and Immunology’s annual meeting this week, two drug juggernauts showcased promising data on their respective anti-inflammatory blockbusters, bolstering approval ambitions at the FDA.

Gilead revealed that Trodelvy has come up short as a first-line treatment for patients with HR+/HER2-negative metastatic breast cancer. The company said that the phase 3 Ascent-07 study comparing Trodelvy to chemotherapy failed to meet its primary endpoint of progression-free survival.

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way last month.

Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune candidates. China will lift the import ban on Illumina’s DNA sequencers. And more.

Merck & Co.’s charitable foundation has committed $22 million to efforts to improve access to care for people with heart disease in the U.S.